Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

This study aimed to identify biomarkers for clinical outcomes in a phase 3 clinical study of blinatumomab or chemotherapy in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Patients were randomized 2:1 to receive blinatumomab, a BiTE(®)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Andrew H., Ribera, Josep-Maria, Larson, Richard A., Ritchie, David, Ghobadi, Armin, Chen, Yuqi, Anderson, Abraham, Dos Santos, Cedric E., Franklin, Janet, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324476/
https://www.ncbi.nlm.nih.gov/pubmed/33542479
http://dx.doi.org/10.1038/s41375-020-01089-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324476/
https://www.ncbi.nlm.nih.gov/pubmed/33542479
http://dx.doi.org/10.1038/s41375-020-01089-x

Ejemplares similares